Get the Stockscreener App
0.00
100.00%
-7.85
Synaptogenix Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Synaptogenix Inc is a biopharmaceutical company with product candidates in pre-clinical and clinical development. It is principally focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease, which is in the clinical testing stage. It is also evaluating bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, Multiple Sclerosis, and Niemann-Pick Type C disease, which have undergone pre-clinical testing.
See More
Previous Close:
$7.85
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$7.07M
Revenue:
-
Net Income/Loss:
$-8.22M
P/E Ratio:
0.00
EPS:
-7.4459
Net Cash Flow:
$-4.78M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$7.85
52-Week Range:
$0.00
$7.85
Synaptogenix Inc Stock (SNPX) Company Profile
Name
Synaptogenix Inc
Sector
Industry
Phone
(973) 242-0005
Address
1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK
Compare SNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNPX
Synaptogenix Inc
|
0.00 | 7.07M | 0 | -8.22M | -4.78M | -7.4459 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.62 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.36 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.91 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
543.48 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Synaptogenix Inc Stock (SNPX) Latest News
Small-cap healthcare stocks with explosive potential - businessnewsthisweek.com
bioAffinity Technologies Stock Price, Quotes and Forecasts | NASDAQ:BIAF - Benzinga
Pre-market Movers: HCTI, KLTO, INTS, HSDT... - RTTNews
This cryptocurrency breaks into the elite of digital assets used as reserves in corporate treasuries. - Bit2Me News
TAO Is Next for Corporate Treasury, Nasdaq Giants Fuel Bittensor’s 10% Rally - Coinspeaker
Bittensor (TAO) Becomes the Next Pick in the Wave of Public Crypto Treasuries - BeInCrypto
Health Care Sector Sees Mixed Results And Strategic Moves - Finimize
Synaptogenix pumps $100m into artificial intelligence token - Mugglehead Magazine
Klotho Neurosciences Sees Massive Jump After Promising Gene Study - Finimize
Synaptogenix (SNPX) Unveils AI-Focused Cryptocurrency Strategy | SNPX Stock News - GuruFocus
Synaptogenix, Inc. announced that it expects to receive $5.5 million in funding - MarketScreener
Synaptogenix Unveils TAO-Focused Crypto Treasury Plan - Live Bitcoin News
Synaptogenix Appoints James Altucher to Lead Digital Asset Treasury Strategy - citybiz
Synaptogenix Says On June 8, Alan Tuchman Resigned As CEO And Director Of Co - MarketScreener
Synaptogenix Launch Of Differentiated Cryptocurrency Treasury Strategy Focused Exclusively On AI Crypto Token 'TAO' - marketscreener.com
Synaptogenix Stock Soars on Bold AI Crypto Bet - RagingBull
Synaptogenix Announces $5.5M Securities Purchase Agreement - TipRanks
Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasu - GuruFocus
Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token | SNPX Stock News - GuruFocus
First Pure-Play AI Crypto Stock: Synaptogenix Commits $100M to Leading AI Token TAO, Appoints Crypto Expert - Stock Titan
Full Stock Market News from 2025-06-06 - Stock Titan
Synaptogenix, Inc. (NASDAQ:SNPX) Short Interest Update - Defense World
Synaptogenix (NASDAQ:SNPX) Trading 1.5% Higher – Here’s What Happened - Defense World
Full Stock Market News from 2025-05-27 - Stock Titan
Full Stock Market News from 2025-05-22 - Stock Titan
SNPXSynaptogenix Latest Stock News & Market Updates - Stock Titan
Geode Capital Management LLC Takes $39,000 Position in Synaptogenix, Inc. (NASDAQ:SNPX) - Defense World
Synaptogenix stock plunges to 52-week low of $2.14 By Investing.com - Investing.com Canada
Synaptogenix stock plunges to 52-week low of $2.14 - Investing.com Australia
Synaptogenix Inc. (SNPX) reports earnings - qz.com
Will Synaptogenix Make A Mark In Synaptic Regeneration? - RTTNews
Synaptogenix stock hits 52-week low at $2.15 amid market challenges - Investing.com Australia
Synaptogenix stock hits 52-week low at $2.15 amid market challenges By Investing.com - Investing.com South Africa
Ensysce Biosciences Stock Price, Quotes and Forecasts | NASDAQ:ENSC - Benzinga
Synaptogenix (NASDAQ:SNPX) Trading Down 0.3% – Here’s Why - Defense World
Sonnet BioTherapeutics Stock Price, Quotes and Forecasts - Benzinga
Mustang Bio Stock Price, Quotes and Forecasts | NASDAQ:MBIO - Benzinga
Aptevo Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:APVO - Benzinga
ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary - Benzinga
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.18% - MSN
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
Synaptogenix Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - Marketscreener.com
Synaptogenix (SNPX) Extends CEO’s Employment and Forms Special Committee to Explore Strategic Opportunities - Defense World
Synaptogenix Forms Special Committee to Explore Strategic Options with $19.6M Cash Runway - StockTitan
Informatica Leads Gartner Magic Quadrant for Data Integration Tools for 19th Straight Year - Stock Titan
Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com
Synaptogenix Announces $5.0 Million Financing - citybiz
Polyrizon Stock Price, Quotes and Forecasts | NASDAQ:PLRZ - Benzinga
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders - PR Newswire
Synaptogenix Inc Stock (SNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):